By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 

1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.


Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 



Industry
Pharmaceutical






Company News
AbbVie (ABBV), Eisai Company (ESALY.PK), And EA Pharma Obtain Additional Approval For New Dosing Regimen Of Fully Human Anti-TNF Monoclonal Antibody Humira In Patients With Crohn's Disease 6/20/2016 9:55:54 AM
AbbVie (ABBV) Teams Up With Leading Nonprofit Organizations To Give Back To Underserved Local Communities 6/20/2016 8:21:34 AM
AbbVie (ABBV) Scholarship Programs Recognize Exceptional Students Living With Chronic Inflammatory Diseases 6/17/2016 10:32:29 AM
AbbVie (ABBV) Declares Quarterly Dividend 6/16/2016 11:28:33 AM
New AbbVie (ABBV) Global Campaign Aims To Provide Educational Resources For Millions Living With Painful, Chronic Skin Disease 6/7/2016 11:58:05 AM
3 Bargain Pharma Stocks to Watch 6/7/2016 7:14:15 AM
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016 2:15:43 PM
ASCO2016 : AbbVie (ABBV) Presents Encouraging Phase 1 Data For Investigational Medicine ABT-414 As Monotherapy In Patients With An Aggressive Brain Cancer At The 2016 American Society Of Clinical Oncology Annual Meeting 6/6/2016 9:55:02 AM
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016 9:42:27 AM
Results Of Phase 1a/1b Study Of AbbVie (ABBV)'s Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate Of 39 Percent In Pretreated Patients With Biomarker-Defined Small Cell Lung Cancer (SCLC) 6/6/2016 8:40:26 AM
12345678910...
//-->